Sign in
ACTU Stock Price, Chart, Stats & News
Actuate Therapeutics Inc
Save
Actuate Therapeutics Inc (ACTU) does not currently pay a dividend.
16.99M
Market cap
–
Current P/E
–
Forward P/E
ACTU chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | -0.00% |
ROA | -158.36% |
ROE | -799.65% |
D/E | 0.05x |
Interest coverage ratio | -1110.84x |
ACTU valuation
P/E | – |
P/S | – |
P/B | 6.31x |
P/CF | -2.58x |
P/FCF | -2.63x |
P/OCF | -2.58x |
PEG | -0.08x |
EV multiple | -2.85x |
About
Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer.
Similar securities
Based on sector and market capitalization
Report issue